Health Affairs, 23, no. 1 (2004): 34-47 doi: 10.1377/hlthaff.23.1.34 © 2004 by Project HOPE	New Online   McAllen, TX & Beyond: An Expert Roundtable   Geography & Reform   Medicaid or Insurance Exchange?   Siren Song of New GME   Public Plan Option: Pro & Con

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (7) Citing Articles via Google Scholar Google Scholar Articles by Kleinke, J.D. Search for Related Content PubMed PubMed Citation Articles by Kleinke, J.D. Related Collections Access To Care Pharmaceuticals Research And Technology Politics

Industry Priorities

Access Versus Excess: Value-Based Cost Sharing For Prescription Drugs

The preponderance of published medical literature and clinical guidelines compels the expansion of pharmaceutical use among Americans, at the same time that private and public health plans seek to restrict such use. The emerging collision course between the march of medical science and the countermarch of medical policy arises from diverging views about the optimal use of drugs and growing philosophical conflict over the abundance and inequities that characterize the U.S. health care system. The consequent turmoil in the market’s approach to managing drug benefits can be remedied through adoption of a value-based (rather than price-based) approach to pharmaceutical spending.

                      What's this?

This article has been cited by other articles:

				D. U. Himmelstein, S. Woolhandler, J. C. Goodman, and R. M. Sade Our Health Care System at the Crossroads: Single Payer or Market Reform? Ann. Thorac. Surg., November 1, 2007; 84(5): 1435 - 1446. [Full Text] [PDF]

				M. E. Chernew, A. B. Rosen, and A. M. Fendrick Value-Based Insurance Design Health Aff., March 1, 2007; 26(2): w195 - w203. [Abstract] [Full Text] [PDF]

				J. C. Goodman What Is Consumer-Directed Health Care? Health Aff., November 1, 2006; 25(6): w540 - w543. [Abstract] [Full Text] [PDF]

				F. Simon Market Access For Biopharmaceuticals: New Challenges Health Aff., September 1, 2006; 25(5): 1363 - 1370. [Abstract] [Full Text] [PDF]

				N. E. Morden and S. D. Sullivan States' Control Of Prescription Drug Spending: A Heterogeneous Approach Health Aff., July 1, 2005; 24(4): 1032 - 1038. [Abstract] [Full Text] [PDF]

				J.D. Kleinke Turning Point For The Health Care Blame Cycle? Health Aff., January 1, 2005; 24(1): 291 - 293. [Full Text] [PDF]